Full Text
Do Us Payers Consider Cost-Effectiveness when Defining Prescription Benefits? A Study of Targeted Therapies for Rheumatoid Arthritis and Moderate-To-Severe Psoriasis

Abstract

Authors

P Borga G Pinedo-Martin A Ribeiro

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×